Pharma Trades Not Deterred by Uncertainty

Chidem Kurdas

Despite legal and market challenges, pharmaceutical and biotech stocks remain a wellspring of investment strategies. A popular play recently

DE Shaw Prevails in Fee Competition

Chidem Kurdas

For many years, hedge fund investors were willing to pay 2/20 or even higher fees to established managers with good track records. New or small funds could be less expensive, but typically not the known names. That appears to be changing.